New bispecific antibodies in diffuse large B-cell lymphoma

Area of Science:

• Oncology
• Immunotherapy
• Hematology

Background:

• Diffuse large B-cell lymphoma (DLBCL) is a significant hematologic malignancy.
• Relapsed or refractory DLBCL presents a challenge with limited treatment options.
• CD20xCD3 T-cell-engaging bispecific antibodies represent a novel therapeutic class.

Purpose of the Study:

• To review the clinical development of CD20xCD3 bispecific antibodies in DLBCL.
• To analyze the efficacy and safety of advanced bispecific antibody agents.
• To explore resistance mechanisms and future directions for these therapies.

Main Methods:

• Review of clinical trial data (Phase I and II) for CD20xCD3 bispecific antibodies.
• Analysis of approved and developing agents including epcoritamab, glofitamab, odronextamab, and mosunetuzumab.
• Examination of combination strategies with immunotherapies and chemotherapy.

Main Results:

• Several CD20xCD3 bispecific antibodies (epcoritamab, glofitamab, odronextamab, mosunetuzumab) are approved or in development for DLBCL.
• These agents demonstrate efficacy as monotherapy and in combination, with a promising role in earlier treatment lines.
• Safe combination profiles with other treatments are established, expanding therapeutic potential.

Conclusions:

• CD20xCD3 bispecific antibodies are a rapidly advancing treatment modality for DLBCL.
• Understanding resistance mechanisms is crucial for optimizing their use.
• Ongoing trials and combinations will define the future role of these antibodies in DLBCL treatment sequences.